[1]杲春阳 宋昌梅 付燕来 张晋.中西医结合治疗新型冠状病毒肺炎疗效的系统评价[J].陕西中医药大学学报,2021,44(01):001-9.[doi:10.13424/j.cnki.jsctcm.2021.01.001]
　GAO Chun-yang,SONG Chang-mei,FU Yan-lai,et al.Curative Effect on Treating COVID-19 by Integrated Medicine: A Systematic Review[J].Journal of Shaanxi University of Traditional Chinese Medicine,2021,44(01):001-9.[doi:10.13424/j.cnki.jsctcm.2021.01.001]
点击复制

中西医结合治疗新型冠状病毒肺炎疗效的系统评价()
分享到：

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
44
期数:
2021年01期
页码:
001-9
栏目:
出版日期:
2021-01-30

文章信息/Info

Title:
Curative Effect on Treating COVID-19 by Integrated Medicine: A Systematic Review
文章编号:
2096-1340(2021)01-0001-09
作者:
杲春阳 宋昌梅 付燕来 张晋
中国中医科学院西苑医院,北京 100091
Author(s):
GAO Chun-yang;  SONG Chang-mei;  FU Yan-lai;  ZHANG Jin
Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing 100091,China
关键词:
新型冠状病毒肺炎; COVID-19; 中西医结合;  Meta 分析; 系统评价
Keywords:
New coronary virus pneumonia;  COVID - 19;  Integrated Medicine;  Meta - analysis;  Systematic Review
分类号:
R256.1
DOI:
10.13424/j.cnki.jsctcm.2021.01.001
文献标志码:
A
摘要:
目的 系统评价中西医结合治疗新型冠状病毒肺炎的疗效。 方法 计算机检索中文数据库中有关中 西医结合治疗新冠肺炎的研究,检索时间均自2019年12月12日-2020年3月25日。由两位评价员独立检索 文献、筛选文献、提取资料和评价纳入研究的偏倚风险后,采用 Stata15.1 软件进行 Meta分析。 结果 共纳入12项研究,4 项 RCT,8 项非随机对照研究,全部研究对象共912例。Meta分析结果显示:与单纯西药相比,中西医 结合治疗新冠肺炎总有效率提高(RR=1.313,95% CI(1.105,1.560),P=0.002),临床症状总积分前后差值增加(SMD=0.818,95% CI(0.03,1.606),P=0.042),发热控制率提高(RR=1.296,95% CI(1.161,1.447),P<0.0001),发热持续时间缩短(WMD=- 1.577,95% CI(-1.980,-1.173),P<0.0001),乏力改善率提高(RR =1.553,95% CI(1.213,1.990),P<0.0001),乏力前后积分差值增加(SMD=1.489,95% CI(0.679,2.300),P<0.0001),乏力持续时间缩短(WMD=-1.742,95% CI(-2.006, -1.478),P<0.0001),咳嗽改善率提高(RR=1.653,95% CI(1.341,2.036),P<0.0001),咳嗽前后积分差值增加(SMD=1.951,95% CI(1.127,2.774),P<0. 0001),咳嗽持续时间缩短(WMD=- 1.711,95% CI(-2.303, -1.119),P<0.0001),CT好转率提高(RR=1.278,95% CI(1.040,1.571),P=0.019),转危重率降低(RR = 0. 438,95% CI(0.258,0.673),P<0.0001);发热 前后积分差值、核酸转阴率差异无统计学意义。 结论 中西医结合治疗新冠肺炎在治疗总有效率,临床症状总积 分,发热控制率、持续时间,乏力改善率、前后积分差值、持续时间,咳嗽改善率、前后积分差值、持续时间,CT好转率,转危重率均优于单纯西医组,提示中西医结合治疗新冠肺炎具有一定价值。 但由于纳入研究数量和质量 的限制,有待于进一步考证。
Abstract:
Objective: To give a systematic appraisal of the curative effect on treating COVID - 19 by Integrated Medicine. Methods: To search the relevant studies on the treatment of COVID - 19 with the integration of Chinese and Western Medicine in the Chinese Corpus ranging from December 12th,2019 to March 25th,2020. The Meta - analysis of the data is done by Stata15. 1 until two appraiser independently search and select the documents, then extract the information and evaluate the risk of bias. Results: 912 cases among 12 studies are selected and grouped into 4 RCT and 8 non - random research respectively. The result of Meta shows that the overall curative effect of treatment with Chinese and Western Medicine significantly rise[RR = 1. 313,95% CI(1. 105,1. 560),P = 0. 002],the difference value of clinical syndrome score increase [SMD = 0. 818,95% CI(0. 03,1. 616),P = 0,042],the control rate of fever increases [RR = 1. 296,95% CI(1. 161,1. 447),P < 0. 0001],the duration of fever shortens [ WMD = - 1. 577,95% CI( - 1. 980, - 1. 173),P < 0. 0001],the improvement rate of debilitation increase [RR = 1. 553,95% CI(1. 213,1. 990),P < 0. 0001], the difference value of debilitation increase[SMD = 1. 489,95% CI(0. 679,2. 300),P < 0. 0001],the duration of debilitation shortens[WMD = - 1. 742,95% CI( - 2. 006, - 1. 478),P < 0. 0001],the improvement rate of cough increase[RR = 1. 653,95% CI(1. 341,2. 036),P < 0. 0001],the difference value of cough increase[SMD = 1. 951,95% CI(1. 127,2. 774),P < 0. 0001],the duration of cough shortens[WMD = - 1. 711,95% CI( - 2. 303, - 1. 119),P < 0. 0001],the improvement rate of CT increase[RR = 1. 278,95% CI(1. 040,1. 571),P = 0. 019],the rate of transforming to severe declines[RR = 0. 438,95% CI(0. 258,0. 673),P < 0. 0001];the difference value before and after fever and the difference value of the negative transformation rate have no statistical significance. Conclusion: The overall curative rate, overall clinical symptom scores, the control rate of fever and its duration, the improvement of debilitation, the difference value and its duration, the improvement rate of cough and the difference value as well as its duration, the improvement rate of CT and rate of transforming severe are generally superior to the group treated uniquely by Western Medicine. It is suggested that the treatment of COVID - 19 with the combination of Chinese and Western Medicine is significant. However, the result needs to be further testified since the selected studies are controlled in terms of quantity and quality.

参考文献/References:

[1]詹志来,刘佳,杨伟,等.基于病例分析的中医药治疗新型冠状病毒肺炎疗效评价标准的探索研究[J/OL].中医杂志.http://kns.cnki.net/kcms/detail/11.2166.R.20200312.0949.002.html.
[2]国家卫生健康委员会,国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第七版)[EB/OL].2020,3,3.http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[3]国新办就中医药防治新冠肺炎的重要作用及有效药物举行发布会,2020,3,23.http://www.china.com.cn/zhibo/content_75844688.htm.
[4]程琦,高杉,于春泉.新型冠状病毒肺炎的中西医防治研究进展[J/OL].天津中医药.http://kns.cnki.net/kcms/detail/12.1349.R.20200320.1526.002.html.
[5] Higgins JPT,Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0.The Chorane Collaboration,2011. Available at:http://www.handbook.cochrane.org/.
[6]Stang A. Critical evaluation of the Newcastle - Ottawa scale for theassessment of the quality of nonrandomized studies in meta - analyses[J]. Eur J Epidemiol,2010,25(9):603 - 605.
[8]国家卫生健康委员会,国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第四版)[EB/OL].2020-1-27.http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67.shtml.
[9]国家卫生健康委员会,国家中医药管理局办公室.关于印发新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL].[2020-2-4].http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml.
[10]国家卫生健康委员会,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].2020-2-18.http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
[11]程德忠,王文菊,李毅,等.51例新型冠状病毒肺炎患者应用中药连花清瘟疗效分析:多中心回顾性研究[J/OL].天津中医药.http://kns.cnki.net/kcms/detail/12.1349.R.20200310.1024.004.html.
[12]黄海,赵焰,左星河,等.肺炎一号方、肺炎二号方治疗新型冠状病毒肺炎[J/OL].中医学报.http://kns.cnki.net/kcms/detail/41.1411.R.20200323.1016.002.html.
[13]段璨,夏文广,郑婵娟,等.金花清感颗粒治疗新型冠状病毒感染肺炎的临床观察[J/OL].中医杂志.http://kns.cnki.net/kcms/detail/11.2166.R.20200323.0853.002.html.
[14]丁晓娟,张勇,何东初,等.清肺透邪扶正方治疗新型冠状病毒肺炎的临床疗效及机制研究[J/OL].医药导报.http://kns.cnki.net/kcms/detail/42.1293.R.20200302.1615.002.html.
[15]杨明博,党双锁,黄胜,等.热炎宁合剂治疗新型冠状病毒肺炎的多中心临床观察[J/OL].中国实验方剂学杂志.https://doi.org/10.13422/j.cnki.syfjx.20201321.
[16]瞿香坤,郝树立,马景贺,等.疏风解毒胶囊联合阿比多尔治疗新型冠状病毒肺炎的回顾性研究[J].中草药,2020,57(5):1167-1170.
[17]傅晓霞,林路平,谭行华.透解祛瘟颗粒治疗新型冠状病毒肺炎临床观察[J/OL].中国实验方剂学杂志.https://doi.org/10.13422/j.cnki.syfjx.20201314.
[18]时佳,杨宗国,叶晨,等.中西医结合治疗上海地区49例非危重型新型冠状病毒肺炎临床疗效观察[J/OL].上海中医药杂志.https://doi.org/10.16305/j.1007-1334.2020.04.095.
[19]夏文广,安长青,郑婵娟,等.中西医结合治疗新型冠状病毒肺炎34例临床研究[J]中医杂志,2020,61(5):375-381.
[20]傅晓霞,林路平,谭行华.中西医结合治疗新型冠状病毒肺炎37例临床研究[J/OL].中药新药与临床药理.http://kns.cnki.net/kcms/detail/44.1308.R.20200319.1644.002.html.
[21]吕睿冰,王文菊,李欣.中药连花清瘟治疗新型冠状病毒肺炎疑似病例63例临床观察[J/OL].中医杂志.http://kns.cnki.net/kcms/detail/11.2166.R.20200215.1633.004.html.
[22]姚开涛,刘明瑜,李欣,等.中药连花清瘟治疗新型冠状病毒肺炎的回顾性临床分析[J/OL].中国实验方剂学杂志.https://doi.org/10.13422/j.cnki.syfjx.20201099.
[23]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:168-189.
[24]杨家耀,苏文,乔杰,等.90例普通型新型冠状病毒肺炎患者中医证候与体质分析[J/OL].中医杂志,2020,61(8):645-649.
[25]林琳,唐光华,欧爱华,等.103例SARS住院患者中医证候规律探讨[J]中医杂志,2004,45(1):51-52.
[26]管汉雄,熊颖,申楠茜,等.新型冠状病毒肺炎(COVID-19)临床影像学特征[J/OL].放射学实践.https://doi.org/10.13609/j.cnki.1000-0313.2020.02.001.
[27]钟飞扬,张寒菲,王彬宸,等.新型冠状病毒肺炎的CT影像学表现[J/OL].武汉大学学报(医学版).https://doi.org/10.14188/j.1671-8852.2020.0061.
[28]Wang M,Cao R,Zhang L,et,al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019 - nCoV) in vitro[ J]. Cell Res,2020,30(3): 269 - 271.

相似文献/References:

[1]肖玮 安兴 谢春光 唐健元 黄青松 曾珠 孙增涛.36例新型冠状病毒肺炎(COVID-19)患者舌象观察[J].陕西中医药大学学报,2020,(预出版):001.
　Xiao Wei,An Xing,Xie Chunguang,et al.Observation of the Tongue Manifestation of 36 Cases of COVID-19[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):001.
[2]刘辉 郑帅 陈静 李香闺 井光壮 李凤英 白云峰 任晓梅 张志刚 韩元平张荣强.陕西省新型冠状病毒肺炎的流行特征及中医药防治策略分析[J].陕西中医药大学学报,2020,(预出版):015.
　LIU Hui,ZHENG Shuai,CHEN Jing,et al.Analysis of EpidemioLogical Characteristics of New Coronavirus Pneumonia in Shaanxi Province and Thoughts on Prevention and Treatment of Traditional Chinese Medicine[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):015.
[3]郭亚男 毛靓瑶 鱼涛 *.关于2019新型冠状病毒肺炎的几点思考[J].陕西中医药大学学报,2020,(预出版):032.
　GUO Ya-nan,MAO Jing-yao,YU Tao *.Theoretical Consideration of Corona Virus Disease 2019(COVID-19)[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):032.
[4]赖逸贵李甜英 王强 叶参 范慧婕 张为 杨芳华胡业建.运用《温热病指南集》风温理论诊治新型冠状病毒肺炎[J].陕西中医药大学学报,2020,(预出版):048.
　LAI Yigui,LI Tianying,WANG Qiang,et al.Study on treatment of novel coronavirus pneumonia by wind – warm theory from Guide To Warm - heat Diseases[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):048.
[5]杨薇杨华升 指导:姜良铎.解表法在新型冠状病毒肺炎中的应用分析[J].陕西中医药大学学报,2020,(预出版):054.
　Yang Wei,Yang Huasheng,Jiang Liangduo ..Application of Relieving Exterior Syndrome in the treatment of Coronavirus Disease 2019[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):054.
[6]陈扬苏同生宋琴琴.新型冠状病毒肺炎非药物干预方案汇总分析[J].陕西中医药大学学报,2020,(预出版):067.
　Chen Yang,Su Tongsheng,Song Qinqin.Summary analysis of non - drug intervention programs for COVID -19[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):067.
[7]罗丹 张海明 于兆民 陈瑞*.中医“治未病”理论指导新型 冠状病毒 肺炎防治的思考[J].陕西中医药大学学报,2020,(预出版):089.
[8]罗丹张海明sup>于兆民陈瑞.中医“治未病”理论指导新型冠状病毒肺炎防治的思考[J].陕西中医药大学学报,2020,(02):005.[doi:10.13424/j.cnki.jsctcm.2020.02.002]
　Luo Dan,Zhang Haiming,Yu Zhaoliang,et al.Thoughts on Prevention and Treatment of COVID -19 by TCM Theory of “ Preventive Treatment of Disease”[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):005.[doi:10.13424/j.cnki.jsctcm.2020.02.002]
[9]肖玮 安兴 谢春光 唐健元 黄青松 曾珠 孙增涛.36例新型冠状病毒肺炎(COVID-19)患者舌象观察[J].陕西中医药大学学报,2020,(02):016.[doi:10.13424/j.cnki.jsctcm.2020.02.005]
　Xiao Wei,An Xing,Xie Chunguang,et al.Observation of the Tongue Manifestation of 36 Cases of COVID -19[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):016.[doi:10.13424/j.cnki.jsctcm.2020.02.005]
[10]郭亚男 毛靓瑶鱼涛.关于2019新型冠状病毒肺炎的几点思考[J].陕西中医药大学学报,2020,(03):005.[doi:10.13424/j.cnki.jsctcm.2020.03.002]
　GUO Ya - nan,MAO Jing - yao,YU Tao.Theoretical Consideration of Corona Virus Disease 2019( COVID -19)[J].Journal of Shaanxi University of Traditional Chinese Medicine,2020,(01):005.[doi:10.13424/j.cnki.jsctcm.2020.03.002]

备注/Memo

备注/Memo:
基金项目:第四批全国优秀临床人才项目(国中医药人教发[2017]24号);国家中医药管理局全国中医学术流派传 承工作室第二轮建设项目(国中医人教函[2019]62号)
通讯作者:张晋,中医学博士,主任医师。 E-mail:13911893296@163.Com
更新日期/Last Update: 2021-01-19